Celecoxib modulates nitric oxide and reactive oxygen species in kidney ischemia/reperfusion injury and rat aorta model of hypoxia/reoxygenation

Vascular Pharmacology

Volumn 62, Issue 1, 2014, Pages 24-31

  Senbel, A M ^a   AbdelMoneim, L ^b   Omar, A G ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b PHAROS UNIVERSITY IN ALEXANDRIA   (Egypt)

Author keywords

Celexocib; Hypoxia reoxygenation; Ischemia reperfusion; Nitric oxide; Reactive oxygen species

Indexed keywords

CELECOXIB; CREATININE; CYCLOOXYGENASE 2; GLUTATHIONE; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UREA; CYCLOOXYGENASE 2 INHIBITOR; OXYGEN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CELL DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; HISTOPATHOLOGY; HYPOXIA; IN VITRO STUDY; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; REOXYGENATION; REPERFUSION INJURY; SCORING SYSTEM; TREATMENT RESPONSE; UREA BLOOD LEVEL; VASCULAR RING; VASODILATATION; ANIMAL; CELL HYPOXIA; DRUG EFFECTS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; AORTA; CELL HYPOXIA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIUM, VASCULAR; IN VITRO TECHNIQUES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NITRIC OXIDE; OXYGEN; PYRAZOLES; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; SULFONAMIDES;

EID: 84902181482     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.04.004     Document Type: Article

References (44)

1. Chander V., Chopra K. Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res 2006, 37:19-26.
2. Erbas H., Aydogdu N., Kaymak K. Effects of N-acetylcysteine on arginase, ornithine and nitric oxide in renal ischemia-reperfusion injury. Pharmacol Res 2004, 50:523-527.
3. Patel N.S.A., Cuzzocrea S., Collino M., Chaterjee P.K., Mazzon E., Britti D., et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007, 562:148-154.
4. Nemoto T., Burne M.J., Daniels F., O'Donnell M.P., Crosson J., Berens K., et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 2001, 60:2205-2214.
5. Park H.K., Lee H.W., Lee K.S., Choi J.S., Jeong B.C., Kim H.H. Preventive effects of COX-2 inhibitor, celecoxib on renal tubular injury induced by shock wave lithotriptor. Urol Res 2010, 38(4):223-228.
6. Kitahara M., Eitner F., Ostendorf T., Kunter U., Janssen U., Westenfeld R., et al. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 2002, 13(5):1261-1270.
7. Reichman J., Cohen S., Goldfarb M., Shina A., Rosen S., Brezis M., et al. Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol 2001, 9:387-396.
8. Dey A., Maric C., Kaesemeyer W.H., Zaharis C.Z., Stewart J., Pollock J.S., et al. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci 2004, 107:561-570.
9. Bonventre J.V., Zuk A. Ischemic acute renal failure: an inflammatory disease & quest. Kidney Int 2004, 66:480-485.
10. Feitoza C.Q., Câmara N.O.S., Pinheiro H.S., Gonçalves G.M., Cenedeze M.A., Pacheco-Silva A., et al. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol 2005, 5:79-84.
11. Feitoza C.Q., Gonçalves G.M., Semedo P., Cenedeze M.A., Pinheiro H.S., Beraldo F.C., et al. Inhibition of COX1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med 2008, 14(11-12):724-730.
12. Shoskes D. Nonimmunologic renal allograft injury and delayed graft function: clinical strategies for prevention and treatment. Transplant Proc 2000, 32(4):766-768.
13. Fawcett J., Scott J.E. A rapid and precise method for the determination of urea. J Clin Pathol 1960, 13:156-159.
14. Varley H., Gowenlock A.H., Bell M. Non-protein nitrogen, urea, urate, creatine and creatinine. Practical clinical biochemistry 1980, 479-481. William Heinemann Medical Books, LTD, London. 5th ed.
15. Habibey R., Ajami M., Ebrahimi S.A., Hesami A., Babakoohi S., Pazoki-Toroudi H. Nitric oxide and renal protection in morphine-dependent rats. Free Radic Biol Med 2010, 49:1109-1118.
16. Placer Z.A., Cushman L.L., Johnson B.C. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 1966, 16:359-364.
17. Richardson R.J., Murphy S.D. Effect of glutathione depletion on tissue deposition of methylmercury in rats. Toxicol Appl Pharmacol 1975, 31:505-519.
18. Moshage H., Kok B., Huizenga J.R., Jansen P. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995, 41:892-896.
19. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974, 47:469-474.
20. Varley H., Gowenlock A.H., Bell M. The plasma proteins. Practical clinical biochemistry 1980, 542-548. William Heinemann Medical Books, LTD, London. 5th ed.
21. Nagao T., Illiano S., Vanhoutte P.M. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-l-arginine in rats. Am J Physiol Heart Circ Physiol 1992, 263:H1090-H1094.
22. Legrand M., Mik E.G., Johannes T., Payen D., Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med 2008, 14:502-516.
23. Hauser B., Froba G., Bracht H., Strater J., Chkhouta A.B., Vassilev D., et al. Effects of intrarenal administration of the COX-2 inhibitor parecoxib during porcine suprarenal aortic cross-clamping. Shock 2005, 24(5):476-481.
24. O'banion M. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999, 13(1):45-82.
25. Ozturk H., Gezici A. The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res 2006, 34(2):76-83.
26. Chenevard R., Hürlimann D., Béchir M., Enseleit F., Spieker L., Hermann M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405-409.
27. Shao J., Sheng H., Inoue H., Morrow J.D., DuBois R.N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000, 275:33951-33956.
28. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24(2):96-102.
29. Chun K.S., Surh Y.J. Signal transduction pathways regulating cyclo-oxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100.
30. Shishodia S., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of I-κB α kinase in human non-small cell lung carcinoma correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004, 64:5004-5012.
31. Armstead W.M. Cyclooxygenase-2-dependent superoxide generation contributes to age-dependent impairment of G protein-mediated cerebrovasodilation. Anesthesiology 2003, 98(6):1378-1383.
32. Ceron C., Castro M., Rizzi E., Montenegro M., Fontana V., Salgado M., et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010, 160(1):77-87.
33. Ochodnický P., Henning R.H., Buikema H.J., De Zeeuw D., Provoost A.P., Van Dokkum R.P.E. Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. Am J Physiol Ren Physiol 2010, 298(3):F625-F633.
34. Yao L.C.S., Toque H.A., Bhatta A., Rojas M., Caldwell R.B., Caldwell R.W. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 2013, 97(3):509-519.
35. El-Metwally M., Sharabi F., Daabees T., Senbel A., Mostafa T. Involvement of α-receptors and potassium channels in the mechanism of action of sildenafil citrate. Int J Impot Res 2007, 19(6):551-557.
36. Teixeira C.E., Priviero F.B.M., Webb R.C. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006, 316(2):654-661.
37. Schäfer A., Fraccarollo D., Pförtsch S., Flierl U., Vogt C., Pfrang J., et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 2008, 153(5):886-893.
38. Sirmagul B., Ilgin S., Atli O., Usanmaz S.E., Demirel-Yilmaz E. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension. Clin Exp Hypertens 2013, 35(3):220-227.
39. Tahseldar-Roumieh R., Keravis T., Maarouf S., Justiniano H., Sabra R., Lugnier C. PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization. Int Pathol 2009, 90(6):605-614.
40. Hermann M., Camici G., Fratton A., Hurlimann D., Tanner F.C., Hellermann J.P., et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003, 108:2308-2311.
41. Klein T., Eltze M., Grebe T., Hatzelmann A., Kömhoff M. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 2007, 75:390-397.
42. Soh J.W., Kazi J.U., Li H., Thompson W.J., Weinstein I.B. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2008, 47(7):519-525.
43. Thiesson H.C., Jensen B.L., Jespersen B., de Muckadell O.B.S., Bistrup C., Walter S., et al. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Ren Physiol 2005, 288(5):F1044-F1052.
44. Leido-Garcia E., Rodriguez-Martinez D., Cabello-Benavente R., Moncada-Iribarren I., Tejedor-Jorge A., Dulin E., et al. Sildenafil improves immediate posttransplant parameters in warm-ischemic kidney transplants: experimental study. Transplant Proc 2007, 39(5):1354-1356.